Is Cell Point overvalued or undervalued?

As of 3 November 2025, the valuation grade for Cell Point has moved from expensive to fair, indicating a more favorable assessment of its market position. The company is currently considered fairly valued. Key ratios include a PE ratio of 90.91, an EV to EBITDA of 9.88, and a Price to Book Value of 0.45, which suggests that while the earnings multiple is high, the asset valuation is relatively low.
In comparison to its peers, Cell Point's valuation stands out against Elitecon International, which is deemed very expensive with a PE ratio of 358.31, and PTC India, which is very attractive with a PE ratio of 7.99. The significant disparity in PE ratios highlights Cell Point's relative valuation position within the retailing industry. Notably, the stock has underperformed against the Sensex over the past year, with a return of -44.62% compared to the Sensex's 6.00%, reinforcing the notion that the stock may have room for recovery given its current fair valuation status.